CervoMed Inc.CRVONASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank64
5Y CAGR-17.7%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-17.7%/yr
Long-term compound
Percentile
P64
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 16.06% |
| 2024 | 122.77% |
| 2023 | 531.40% |
| 2022 | -84.28% |
| 2021 | -9.85% |
| 2020 | 42.42% |
| 2019 | 15.09% |
| 2018 | 13.03% |
| 2017 | -18.60% |
| 2016 | 61.34% |